You’ve Already Paid $6 Billion For Weight-Loss Drugs You Can’t Afford
U.S. taxpayers spent billions developing Ozempic-type diabetes and weight-loss drugs — now those drugs’ markups could bankrupt the U.S. health care system.
Business
Critical coverage on the global financial system and domestic policies that shape the U.S. economy, with a focus on corporate wrongdoing.
The Billion-Dollar Taxpayer Math Behind The Ozempic Boom
How Americans spent $6.2 billion to develop overpriced diabetes and weight-loss drugs.
The Looting Of America’s Affordable Housing Fund
Private equity firms are diverting billions from a Great Depression-era mortgage program — and making huge profits.
The Devil In Your Cereal Bowl
Why a controversial chemical is tainting your foods — and what you can do to protect yourself.
The Plan To Make America Hazardous Again
Trump’s EPA could stop states from warning people about potentially dangerous chemicals sprayed on their food.
YOU LOVE TO SEE IT: Microplastics Meet Their Match
Your fruit bowl comes to the rescue, traffic tax hits the jackpot, anti-abortion activists get buffered, and the Granite State goes green.
The Red State Workers Caught In Trump’s EV Battle
Many clean energy boom towns voted for Trump. Will his administration put them at risk?
On The Line In The Battery Belt
EV plant workers share the risks, rewards, and uncertainties of working toward “the future of the automotive industry” amid Trump-related upheaval.
The Battle For Musk’s Lair
States are quietly weakening corporate accountability to lure Elon Musk and other business interests.
YOU LOVE TO SEE IT: “Today I Am Finally Free”
A legendary activist is released, an arms race slows down, abortion providers get their license, and shoppers dump their toxic exes.